About us

Our name Enara Bio™ is derived from an Arabic word meaning illumination, enlightenment and bringing light into the darkness.

We are the leaders in exploring the hidden depths of cancer and T-cell biology to discover and characterize Dark Antigens™, a novel class of shared immunotherapy targets that arise from altered cellular processes in cancer cells. We believe that Dark Antigens have the core attributes that will enable cancer immunotherapies to improve treatment outcomes for broad patient populations.

Enara Bio is backed by prominent life science investors, including RA Capital, Samsara Biocapital and SV Health Investors. We collaborate with world-leading companies and academic institutions, such as Boehringer Ingelheim and the Francis Crick Institute, to help drive our differentiated science-led approach.

Enara Bio Our Story Poster

Leadership Team

Andrew Fadden
Chief Business Officer
Kevin Pojasek
President and Chief Executive Officer
David Watson
Chief Operating Officer
Sophie Papa
Chief Medical Officer and Head of Translational Science
Joseph Dukes
Chief Scientific Officer

Board of Directors

Scientific Advisory Board

Robert Ang


Robert Ang brings more than 20 years of executive leadership, strategy consulting and investing experience in the biopharma industry. He currently serves as the President and Chief Executive Officer of Vor Biopharma, a clinical-stage cell and genome engineering company based in Cambridge, MA where he has led a successful Series B fundraising and a subsequent NASDAQ IPO.

Prior to Vor, Robert was Chief Business Officer at Neon Therapeutics, where he was responsible for strategy, business development, financing, collaborations, intellectual property and other functions, raising over $125M in private financing and $100M in gross proceeds from an IPO. Robert also served as the SVP of Business Development at Bavarian Nordic and was responsible for conducting the licensing transaction between Bavarian Nordic and Bristol-Myers Squibb for PROSTVAC. Robert has operational experience from Cadence Pharmaceuticals and Cure Therapeutics, and venture capital experience at Frazier Healthcare Ventures and Carrot Capital with five investments generating cash-on-cash returns of over three times.

Robert holds a medical degree from the University of Western Australia, trained in general surgery, and received an MBA with Honors from Columbia Business School.